Swept source optical coherence tomography angiography of neovascular macular telangiectasia type 2

Retina

Volumn 35, Issue 11, 2015, Pages 2285-2299

  Zhang, Qinqin ^a   Wang, Ruikang K ^a   Chen, Chieh Li ^a   Legarreta, Andrew D ^b   Durbin, Mary K ^c   An, Lin ^c   Sharma, Utkarsh ^c   Stetson, Paul F ^c   Legarreta, John E ^b   Roisman, Luiz ^b   Gregori, Giovanni ^b   Rosenfeld, Philip J ^b  

^a University of Washington   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c CARL ZEISS SMT AG   (Germany)

Author keywords

Angiography; MacTel; Neovascular; OMAG; SSOCT

Indexed keywords

BEVACIZUMAB; COLORING AGENT; INDOCYANINE GREEN;

ADULT; ARTICLE; BRUCH MEMBRANE; CHOROID CAPILLARY LAYER; COMPARATIVE STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; INDOCYANINE GREEN ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MICROANGIOGRAPHY; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; RETINA DISEASE; RETINA FLUORESCEIN ANGIOGRAPHY; RETINAL TELANGIECTASIA TYPE 2; SUBRETINAL NEOVASCULARIZATION; TELANGIECTASIA; VISUAL IMPAIRMENT; CASE REPORT; CHOROID; FLUORESCENCE ANGIOGRAPHY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RETINA BLOOD VESSEL; RETINAL NEOVASCULARIZATION; RETINAL TELANGIECTASIS; VASCULARIZATION; VISUAL ACUITY;

CHOROID; COLORING AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL NEOVASCULARIZATION; RETINAL TELANGIECTASIS; RETINAL VESSELS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84946053322     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000840     Document Type: Article

References (35)

1. Yannuzzi LA, Bardal AM, Freund KB, et al. Idiopathic macular telangiectasia. Arch Ophthalmol 2006;124:450-460.
2. Wu L, Evans T, Arevalo JF. Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2). Surv Ophthalmol 2013;58:536-559.
3. Aung KZ, Wickremasinghe SS, Makeyeva G, et al. The prevalence estimates of macular telangiectasia type 2: the Melbourne Collaborative Cohort Study. Retina 2010;30:473-478.
4. Klein R, Blodi BA, Meuer SM, et al. The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study. Am J Ophthalmol 2010;150:55-62.e2.
5. Clemons TE, Gillies MC, Chew EY, et al. Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2. Ophthalmic Epidemiol 2010;17:66-73.
6. Sallo FB, Leung I, Chung M, et al. Retinal crystals in type 2 idiopathic macular telangiectasia. Ophthalmology 2011;118: 2461-2467.
7. Zhu M, Krilis M, Gillies MC. The relationship between inner retinal cavitation, photoreceptor disruption, and the integrity of the outer limiting membrane in macular telangiectasia type 2. Retina 2013;33:1547-1550.
8. Surguch V, Gamulescu MA, Gabel VP. Optical coherence tomography findings in idiopathic juxtafoveal retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 2007;245:783-788.
9. Gaudric A, Ducos de Lahitte G, Cohen SY, et al. Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 2006;124:1410-1419.
10. Paunescu LA, Ko TH, Duker JS, et al. Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography. Ophthalmology 2006;113:48-57.
11. Koizumi H, Iida T, Maruko I. Morphologic features of group 2A idiopathic juxtafoveolar retinal telangiectasis in threedimensional optical coherence tomography. Am J Ophthalmol 2006;142:340-343.
12. Baumuller S, Charbel Issa P, Scholl HP, et al. Outer retinal hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2. Ophthalmology 2010;117:2162-2168.
13. Sallo FB, Peto T, Egan C, et al. The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci 2012;53:7889-7895.
14. Sallo FB, Peto T, Egan C, et al. "En face" OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci 2012;53:6145-6152.
15. Mathew R, Sivaprasad S, Florea D, et al. Agreement between time-domain and spectral-domain optical coherence tomography in the assessment of macular thickness in patients with idiopathic macular telangiectasia type 2. Ophthalmologica 2013;230:144-150.
16. Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 1982;100:769-780.
17. Schmitz-Valckenberg S, Ong EE, Rubin GS, et al. Structural and functional changes over time in MacTel patients. Retina 2009;29:1314-1320.
18. Thorell MR, Zhang Q, Huang Y, et al. Swept-source OCT angiography of macular telangiectasia type 2. Ophthalmic Surg Lasers Imaging Retina 2014;45:369-380.
19. Spaide RF, Klancnik JM Jr., Cooney MJ. Retinal vascular layers in macular telangiectasia type 2 imaged by optical coherence tomographic angiography. JAMA Ophthalmol 2015;133:66-73.
20. Charbel Issa P, Holz FG, Scholl HP. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 2007;114:1736-1742.
21. Charbel Issa P, Finger RP, Holz FG, Scholl HP. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 2008;92:941-945.
22. Gamulescu MA, Walter A, Sachs H, Helbig H. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 2008;246:1189-1193.
23. Kovach JL, Rosenfeld PJ. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 2009; 29:27-32.
24. Roller AB, Folk JC, Patel NM, et al. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 2011;31:1848-1855.
25. Lira RP, Silva VB, Cavalcanti TM, et al. Intravitreous ranibizumab as treatment for macular telangiectasia type 2. Arch Ophthalmol 2010;128:1075-1078.
26. Charbel Issa P, Finger RP, Kruse K, et al. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol 2011;151:876-886.e1.
27. Toy BC, Koo E, Cukras C, et al. Treatment of non-neovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial. Retina 2012;32: 996-1006.
28. Do DV, Bressler SB, Cassard SD, et al. Ranibizumab for macular telangiectasia type 2 in the absence of subretinal neovascularization. Retina 2014;34:2063-2071.
29. Huang Y, Zhang Q, Thorell MR, et al. Swept-source OCT angiography of the retinal vasculature using intensity differentiation-based optical microangiography algorithms. Ophthalmic Surg Lasers Imaging Retina 2014;45:382-389.
30. Wang RK, An L, Francis P, Wilson DJ. Depth-resolved imaging of capillary networks in retina and choroid using ultrahigh sensitive optical microangiography. Opt Lett 2010;35:1467-1469.
31. An L, Subhush HM, Wilson DJ, Wang RK. High-resolution wide-field imaging of retinal and choroidal blood perfusion with optical microangiography. J Biomed Opt 2010;15:026011.
32. Wang RK, Jacques SL, Ma Z, et al. Three dimensional optical angiography. Opt Express 2007;15:4083-4097.
33. Wang RK, Hurst S. Mapping of cerebro-vascular blood perfusion in mice with skin and skull intact by Optical Micro-AngioGraphy at 1.3 mum wavelength. Opt Express 2007;15: 11402-11412.
34. An L, Wang RK. In vivo volumetric imaging of vascular perfusion within human retina and choroids with optical microangiography. Opt Express 2008;16:11438-11452.
35. Yin X, Chao JR, Wang RK. User-guided segmentation for volumetric retinal optical coherence tomography images. J Biomed Opt 2014;19:086020.